Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2 –, PIK3CA-mutated breast cancers

ConclusionsOur study establishes clonal multiplePIK3CAmut as an important molecular determinant of response to p110 α inhibition and provides rationale for further clinical investigation of p110α inhibitors alone or with rationally-selected therapies in breast cancer and potentially other solid tumor types.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research